SAN DIEGO, Aug. 6, 2016 /PRNewswire/ — Johnson & Weaver, LLP, based in San Diego California with offices in New York, New York, and Marietta, Georgia, is investigating potential violations of the federal securities laws by EndoChoice Holdings, Inc. (NYSE: GI) and certain of its officers and directors. EndoChoice is a medical device company based in Alpharetta, Georgia.
Specifically, Johnson & Weaver’s investigation seeks to determine whether the Company’s filings with the U.S. Securities and Exchange Commission in connection with EndoChoice’s June 5, 2015 initial public offering (“IPO”) contained untrue statements of material facts or omitted to state other facts necessary to make the statements made therein not misleading concerning the Company’s business and financial prospects.
On or about June 5, 2015, EndoChoice issued over 6.35 million shares of common stock at $15 per share, raising more than $95 million in gross proceeds. Since the IPO, EndoChoice stock has plummeted. Most recently, on August 4, 2016, the stock closed down over 21% at $4.13 per share after disappointing second quarter earnings were reported.
If you are an, EndoChoice shareholder and are interested in learning more about your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) at 619-814-4471. If you email, please include your phone number.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.
Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com